Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer Metastatic
Interventions: DRUG: Ceralasertib|DRUG: Durvalumab|DRUG: Nab-paclitaxel
Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology
Collaborators: AstraZeneca